The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Kathy D. Miller

Indiana University Cancer Center

Indianapolis

USA

[email]@iupui.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Indiana University Cancer Center, Indianapolis, USA. 2002 - 2007
  • Division of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, USA. 2001 - 2006
  • Hoosier Oncology Group and the Walther Cancer Institute, Indianapolis, USA. 1999

References

  1. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A., Shenkier, T., Cella, D., Davidson, N.E. N. Engl. J. Med. (2007) [Pubmed]
  2. A physiologic imaging pilot study of breast cancer treated with AZD2171. Miller, K.D., Miller, M., Mehrotra, S., Agarwal, B., Mock, B.H., Zheng, Q.H., Badve, S., Hutchins, G.D., Sledge, G.W. Clin. Cancer Res. (2006) [Pubmed]
  3. Can tumor angiogenesis be inhibited without resistance?. Miller, K.D., Sweeney, C.J., Sledge, G.W. EXS (2005) [Pubmed]
  4. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. Miller, K.D., Chap, L.I., Holmes, F.A., Cobleigh, M.A., Marcom, P.K., Fehrenbacher, L., Dickler, M., Overmoyer, B.A., Reimann, J.D., Sing, A.P., Langmuir, V., Rugo, H.S. J. Clin. Oncol. (2005) [Pubmed]
  5. Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Miller, K.D., Soule, S.E., Calley, C., Emerson, R.E., Hutchins, G.D., Kopecky, K., Badve, S., Storniolo, A., Goulet, R., Sledge, G.W. Breast Cancer Res. Treat. (2005) [Pubmed]
  6. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Miller, K.D., Trigo, J.M., Wheeler, C., Barge, A., Rowbottom, J., Sledge, G., Baselga, J. Clin. Cancer Res. (2005) [Pubmed]
  7. A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer. Miller, K.D., Soule, S.E., Haney, L.G., Guiney, P., Murry, D.J., Lenaz, L., Sun, S.L., Sledge, G.W. Invest. New. Drugs (2004) [Pubmed]
  8. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Miller, K.D., Saphner, T.J., Waterhouse, D.M., Chen, T.T., Rush-Taylor, A., Sparano, J.A., Wolff, A.C., Cobleigh, M.A., Galbraith, S., Sledge, G.W. Clin. Cancer Res. (2004) [Pubmed]
  9. Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?. Miller, K.D. Breast Cancer Res. (2004) [Pubmed]
  10. The role of ErbB inhibitors in trastuzumab resistance. Miller, K.D. Oncologist (2004) [Pubmed]
  11. Breast cancer: the role of angiogenesis and antiangiogenic therapy. Miller, K.D., Dul, C.L. Hematol. Oncol. Clin. North Am. (2004) [Pubmed]
  12. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Miller, K.D. Clin. Breast Cancer (2003) [Pubmed]
  13. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Miller, K.D., Weathers, T., Haney, L.G., Timmerman, R., Dickler, M., Shen, J., Sledge, G.W. Ann. Oncol. (2003) [Pubmed]
  14. A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Miller, K.D., Gradishar, W., Schuchter, L., Sparano, J.A., Cobleigh, M., Robert, N., Rasmussen, H., Sledge, G.W. Ann. Oncol. (2002) [Pubmed]
  15. Issues and challenges for antiangiogenic therapies. Miller, K.D. Breast Cancer Res. Treat. (2002) [Pubmed]
  16. Redefining the target: chemotherapeutics as antiangiogenics. Miller, K.D., Sweeney, C.J., Sledge, G.W. J. Clin. Oncol. (2001) [Pubmed]
  17. Selection bias in clinical trials. Miller, K.D., Rahman, Z.U., Sledge, G.W. Breast. Dis (2001) [Pubmed]
  18. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. Miller, K.D., McCaskill-Stevens, W., Sisk, J., Loesch, D.M., Monaco, F., Seshadri, R., Sledge, G.W. J. Clin. Oncol. (1999) [Pubmed]
 
WikiGenes - Universities